A Glimmer of Hope in the Pancreatic Cancer Crisis The FDA's approval of daraxonrasib, a once daily pill that blocks RAS proteins, has sent shockwaves through the medical community.
This breakthrough treatment has been shown to double patient survival time when compared to standard chemotherapy.
Pancreatic adenocarcinoma, the most common form of pancreatic cancer, is a formidable foe that claims over 67,000 lives annually in the United States.